Tallimustine
Also known as: Distamycin A nitrogen mustard analogue, FCE 24517
Source Tallimustine at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Tallimustine (FCE 24517) is an experimental antineoplastic peptide-polyamide conjugate derived from distamycin A coupled to a benzoyl nitrogen mustard moiety. It demonstrates potent cytotoxic activity with sequence-selective DNA minor groove alkylation. Phase I and II clinical trials were conducted in the 1990s–2000s for various solid tumors and hematologic malignancies, but development was halted primarily due to dose-limiting myelosuppression. It remains a research/investigational compound and is not approved for clinical use.
Mechanism of Action
Tallimustine is a benzoyl nitrogen mustard derivative of the natural antibiotic distamycin A. It binds to the minor groove of DNA with sequence selectivity (preferring AT-rich sequences, particularly at the N3 of adenine in runs of four or more AT base pairs) and alkylates DNA, leading to DNA strand breaks, inhibition of replication, and apoptosis in rapidly dividing cells.
Routes of Administration
Goals & Uses
- Solid tumor treatmentOncologyLow
- Sequence-selective DNA alkylation researchResearchModerate
- Hematologic malignancy treatmentOncologyLow
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Pre-existing severe bone marrow suppressionHematologicHigh
- Severe renal impairmentOrganModerateKidney function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- HepatotoxicityHepaticUncommonLiver injury or dysfunction
- AlopeciaDermatologicUncommonHair loss
- Nausea and vomitingGastrointestinalCommon
- MucositisGastrointestinal / MucosalUncommon
- Myelosuppression (neutropenia, thrombocytopenia)HematologicCommon
- Fatigue/astheniaGeneralCommon
Drug Interactions
- Live attenuated vaccinesHigh
- Other myelosuppressive agentsHigh
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveAbsolute
- Elderly patientsAgeRelative
Regulatory Status
- European UnionInvestigationalClinical trials conducted in European centers; no marketing authorization ever granted.
- United StatesInvestigationalStudied under IND in Phase I/II trials; never approved by FDA.
- United KingdomInvestigationalNo approval; remained investigational only.
Never received regulatory approval in any jurisdiction. Investigated under clinical trial frameworks in Europe and the United States. Development was discontinued; no approved indications exist.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Tallimustine?
Tallimustine (FCE 24517) is an experimental antineoplastic peptide-polyamide conjugate derived from distamycin A coupled to a benzoyl nitrogen mustard moiety. It demonstrates potent cytotoxic activity with sequence-selective DNA minor groove alkylation. Phase I and II clinical trials were conducted in the 1990s–2000s for various solid tumors and hematologic malignancies, but development was halted primarily due to dose-limiting myelosuppression. It remains a research/investigational compound and is not approved for clinical use.
What is Tallimustine used for?
Tallimustine is educationally associated with: Solid tumor treatment, Sequence-selective DNA alkylation research, Hematologic malignancy treatment. Educational only — not medical advice.
How is Tallimustine administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Tallimustine?
Reported adverse effects include: Hepatotoxicity, Alopecia, Nausea and vomiting, Mucositis, Myelosuppression (neutropenia, thrombocytopenia), Fatigue/asthenia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Tallimustine?
Recorded contraindications: Severe hepatic impairment, Pre-existing severe bone marrow suppression, Severe renal impairment, Pregnancy. Consult a qualified clinician before use.